Jon Lim, FRCP PhD
@drjonlim.bsky.social
Senior Lecturer & Consultant Medical Oncologist in Advanced #Immunotherapy + #CellTherapy at @manchester.ac.uk & The Christie • RISE Lead & MANIFEST Deputy Lead • ESMO #TranslationalResearch Faculty
🔗 Bio: bit.ly/Christie_JLim
(tennis enthusiast 🎾)
🔗 Bio: bit.ly/Christie_JLim
(tennis enthusiast 🎾)
Pinned
My main PhD paper is finally out! 🎉
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
🎓 New PhD Opportunity
An exciting PhD opportunity at the Cancer Research UK Manchester Centre, supporting the next generation of leaders in cancer research.
📅 Deadline: Friday 3 April
🔗 For further information & to apply: ow.ly/ZWYs50Y7vHR
@uom-dcs.bsky.social
@manchester.ac.uk
An exciting PhD opportunity at the Cancer Research UK Manchester Centre, supporting the next generation of leaders in cancer research.
📅 Deadline: Friday 3 April
🔗 For further information & to apply: ow.ly/ZWYs50Y7vHR
@uom-dcs.bsky.social
@manchester.ac.uk
February 7, 2026 at 3:49 PM
🎓 New PhD Opportunity
An exciting PhD opportunity at the Cancer Research UK Manchester Centre, supporting the next generation of leaders in cancer research.
📅 Deadline: Friday 3 April
🔗 For further information & to apply: ow.ly/ZWYs50Y7vHR
@uom-dcs.bsky.social
@manchester.ac.uk
An exciting PhD opportunity at the Cancer Research UK Manchester Centre, supporting the next generation of leaders in cancer research.
📅 Deadline: Friday 3 April
🔗 For further information & to apply: ow.ly/ZWYs50Y7vHR
@uom-dcs.bsky.social
@manchester.ac.uk
📣 Final agenda confirmed - only 5 weeks to go!
Join us on 𝟭𝟭 𝗠𝗮𝗿𝗰𝗵 𝟮𝟬𝟮𝟲 in Manchester 🐝 for our inaugural TIL Summit: Unlocking TIL Therapy – A New Era for Melanoma Care in the UK.
Kindly sponsored by The Christie Charity.
Space limited - so don't miss out! For further information & to register:
Join us on 𝟭𝟭 𝗠𝗮𝗿𝗰𝗵 𝟮𝟬𝟮𝟲 in Manchester 🐝 for our inaugural TIL Summit: Unlocking TIL Therapy – A New Era for Melanoma Care in the UK.
Kindly sponsored by The Christie Charity.
Space limited - so don't miss out! For further information & to register:
Unlocking TIL Therapy: A New Era for Melanoma Care in the UK
TIL (Tumour-Infiltrating Lymphocyte) therapy is a transformative, cell-based immunotherapy approach now entering clinical practice for melanoma. This national summit brings together UK and internation...
www.christie.nhs.uk
February 3, 2026 at 2:49 PM
📣 Final agenda confirmed - only 5 weeks to go!
Join us on 𝟭𝟭 𝗠𝗮𝗿𝗰𝗵 𝟮𝟬𝟮𝟲 in Manchester 🐝 for our inaugural TIL Summit: Unlocking TIL Therapy – A New Era for Melanoma Care in the UK.
Kindly sponsored by The Christie Charity.
Space limited - so don't miss out! For further information & to register:
Join us on 𝟭𝟭 𝗠𝗮𝗿𝗰𝗵 𝟮𝟬𝟮𝟲 in Manchester 🐝 for our inaugural TIL Summit: Unlocking TIL Therapy – A New Era for Melanoma Care in the UK.
Kindly sponsored by The Christie Charity.
Space limited - so don't miss out! For further information & to register:
One of the projects I’m most proud of since returning to Manchester.
In awe of the resilience of our Ukrainian colleagues delivering cancer care under extraordinary circumstances, and grateful for the generosity of #TeamManchester colleagues in sharing best practice.
🇬🇧 🤝 🇺🇦
Find out more 👇
In awe of the resilience of our Ukrainian colleagues delivering cancer care under extraordinary circumstances, and grateful for the generosity of #TeamManchester colleagues in sharing best practice.
🇬🇧 🤝 🇺🇦
Find out more 👇
The beginning of an international partnership between The Christie and the National Cancer Institute of Ukraine
The Christie Institute for Cancer Education has welcomed international colleagues from the National Cancer Institute of Ukraine (UNCI) as part of a new education partnership focused on bilateral shari...
www.christie.nhs.uk
February 2, 2026 at 2:51 PM
One of the projects I’m most proud of since returning to Manchester.
In awe of the resilience of our Ukrainian colleagues delivering cancer care under extraordinary circumstances, and grateful for the generosity of #TeamManchester colleagues in sharing best practice.
🇬🇧 🤝 🇺🇦
Find out more 👇
In awe of the resilience of our Ukrainian colleagues delivering cancer care under extraordinary circumstances, and grateful for the generosity of #TeamManchester colleagues in sharing best practice.
🇬🇧 🤝 🇺🇦
Find out more 👇
Reposted by Jon Lim, FRCP PhD
New Journal for ImmunoTherapy of Cancer review: Steroid-sparing strategies for managing immune-related adverse events jitc.bmj.com/content/14/1...
January 26, 2026 at 2:41 PM
New Journal for ImmunoTherapy of Cancer review: Steroid-sparing strategies for managing immune-related adverse events jitc.bmj.com/content/14/1...
Reposted by Jon Lim, FRCP PhD
Exciting conference alert!
sites.manchester.ac.uk/from-lab-to-...
Fantastic speakers including Chris Marine, Christian Blank
Melanoma evolution
Local microenvironment of melanoma
Melanoma-host interactions
Precision immunotherapy
Emerging therapeutics
Clinical trials and real-world data
sites.manchester.ac.uk/from-lab-to-...
Fantastic speakers including Chris Marine, Christian Blank
Melanoma evolution
Local microenvironment of melanoma
Melanoma-host interactions
Precision immunotherapy
Emerging therapeutics
Clinical trials and real-world data
January 22, 2026 at 11:28 PM
Exciting conference alert!
sites.manchester.ac.uk/from-lab-to-...
Fantastic speakers including Chris Marine, Christian Blank
Melanoma evolution
Local microenvironment of melanoma
Melanoma-host interactions
Precision immunotherapy
Emerging therapeutics
Clinical trials and real-world data
sites.manchester.ac.uk/from-lab-to-...
Fantastic speakers including Chris Marine, Christian Blank
Melanoma evolution
Local microenvironment of melanoma
Melanoma-host interactions
Precision immunotherapy
Emerging therapeutics
Clinical trials and real-world data
🆕 New on the ESMO events calendar for 2026!
Mark your calendar for the 𝗘𝗦𝗠𝗢 𝗣𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿𝘀𝗵𝗶𝗽 𝗼𝗻 𝗧𝘂𝗺𝗼𝘂𝗿-𝗔𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗼𝗳 𝗨𝗻𝗸𝗻𝗼𝘄𝗻 𝗣𝗿𝗶𝗺𝗮𝗿𝘆 (𝗖𝗨𝗣) in Zurich: 18-19 September 2026.
Chaired by the fantastic @oncocook.bsky.social & @benwestphalen.bsky.social.
@myesmo.bsky.social
Mark your calendar for the 𝗘𝗦𝗠𝗢 𝗣𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿𝘀𝗵𝗶𝗽 𝗼𝗻 𝗧𝘂𝗺𝗼𝘂𝗿-𝗔𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗼𝗳 𝗨𝗻𝗸𝗻𝗼𝘄𝗻 𝗣𝗿𝗶𝗺𝗮𝗿𝘆 (𝗖𝗨𝗣) in Zurich: 18-19 September 2026.
Chaired by the fantastic @oncocook.bsky.social & @benwestphalen.bsky.social.
@myesmo.bsky.social
January 22, 2026 at 5:14 PM
🆕 New on the ESMO events calendar for 2026!
Mark your calendar for the 𝗘𝗦𝗠𝗢 𝗣𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿𝘀𝗵𝗶𝗽 𝗼𝗻 𝗧𝘂𝗺𝗼𝘂𝗿-𝗔𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗼𝗳 𝗨𝗻𝗸𝗻𝗼𝘄𝗻 𝗣𝗿𝗶𝗺𝗮𝗿𝘆 (𝗖𝗨𝗣) in Zurich: 18-19 September 2026.
Chaired by the fantastic @oncocook.bsky.social & @benwestphalen.bsky.social.
@myesmo.bsky.social
Mark your calendar for the 𝗘𝗦𝗠𝗢 𝗣𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿𝘀𝗵𝗶𝗽 𝗼𝗻 𝗧𝘂𝗺𝗼𝘂𝗿-𝗔𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗼𝗳 𝗨𝗻𝗸𝗻𝗼𝘄𝗻 𝗣𝗿𝗶𝗺𝗮𝗿𝘆 (𝗖𝗨𝗣) in Zurich: 18-19 September 2026.
Chaired by the fantastic @oncocook.bsky.social & @benwestphalen.bsky.social.
@myesmo.bsky.social
This is one of the projects I’m most proud of since coming back to (re-)join #TeamManchester faculty. Delighted to welcome and host our Medical Oncology colleagues from UNCI, Kyiv at The Christie.
🇺🇦 🤝 🇬🇧
🇺🇦 🤝 🇬🇧
We had a fantastic afternoon at our ‘Observers Showcase’ hearing from our final cohort of Ukrainian observers from National Cancer Centre in Kiev.
The group shared some truly inspiring stories of their experiences of delivering oncology care during the war and the challenges it has brought.
The group shared some truly inspiring stories of their experiences of delivering oncology care during the war and the challenges it has brought.
January 18, 2026 at 5:39 PM
This is one of the projects I’m most proud of since coming back to (re-)join #TeamManchester faculty. Delighted to welcome and host our Medical Oncology colleagues from UNCI, Kyiv at The Christie.
🇺🇦 🤝 🇬🇧
🇺🇦 🤝 🇬🇧
🚀 Kicking off the new year with our next #ChristieFellowship session!
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
January 15, 2026 at 9:12 PM
🚀 Kicking off the new year with our next #ChristieFellowship session!
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
Reposted by Jon Lim, FRCP PhD
Thanks to @acir-org.bsky.social for highlighting our article!
January 14, 2026 at 5:43 PM
Thanks to @acir-org.bsky.social for highlighting our article!
Reposted by Jon Lim, FRCP PhD
❗Cross-presentation shapes neoantigen visibility and cancer immunogenicity in #NatureImmunology🤯
www.nature.com/articles/s41...
Huge congratulations @drjonlim.bsky.social 🥂
Inspired and so lucky to have you in #Manchester 🐝
Congratulations to #OliverSchulz, @reisesousalab.bsky.social , @crick.ac.uk
www.nature.com/articles/s41...
Huge congratulations @drjonlim.bsky.social 🥂
Inspired and so lucky to have you in #Manchester 🐝
Congratulations to #OliverSchulz, @reisesousalab.bsky.social , @crick.ac.uk
January 14, 2026 at 10:27 PM
❗Cross-presentation shapes neoantigen visibility and cancer immunogenicity in #NatureImmunology🤯
www.nature.com/articles/s41...
Huge congratulations @drjonlim.bsky.social 🥂
Inspired and so lucky to have you in #Manchester 🐝
Congratulations to #OliverSchulz, @reisesousalab.bsky.social , @crick.ac.uk
www.nature.com/articles/s41...
Huge congratulations @drjonlim.bsky.social 🥂
Inspired and so lucky to have you in #Manchester 🐝
Congratulations to #OliverSchulz, @reisesousalab.bsky.social , @crick.ac.uk
Reposted by Jon Lim, FRCP PhD
NB 'An important function of the immune system is to eradicate pre-malignant and malignant cells in the early phase of tumor development. For this reason, the use of carcinogens rather than transplantable tumor cell lines in mice can offer a more refined experimental approach (...)'
Client Challenge
www.nature.com
January 14, 2026 at 8:40 AM
NB 'An important function of the immune system is to eradicate pre-malignant and malignant cells in the early phase of tumor development. For this reason, the use of carcinogens rather than transplantable tumor cell lines in mice can offer a more refined experimental approach (...)'
How does the immune system decide which tumour antigens remain visible over time❓
Our study on dendritic cell cross-presentation of dead-cell, F-actin–associated antigens, and its impact on tumour immunogenicity and cancer evolution, was featured in @acir-org.bsky.social.
Read further here 👇
Our study on dendritic cell cross-presentation of dead-cell, F-actin–associated antigens, and its impact on tumour immunogenicity and cancer evolution, was featured in @acir-org.bsky.social.
Read further here 👇
DC cross-presentation of dead cell F-actin antigens sculpts tumor evolution
Lim, Schulz, et al. studied the functioning of the F-actin receptor DNGR-1 on cDC1s, and the impact of cross-presentation on immunoediting of tumors using chemical carcinogenesis models. Dead cell-ass...
acir.org
January 14, 2026 at 2:53 PM
How does the immune system decide which tumour antigens remain visible over time❓
Our study on dendritic cell cross-presentation of dead-cell, F-actin–associated antigens, and its impact on tumour immunogenicity and cancer evolution, was featured in @acir-org.bsky.social.
Read further here 👇
Our study on dendritic cell cross-presentation of dead-cell, F-actin–associated antigens, and its impact on tumour immunogenicity and cancer evolution, was featured in @acir-org.bsky.social.
Read further here 👇
🤔 Do patients with cancer and clinicians see disease status the same way?
Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
January 13, 2026 at 5:46 PM
🤔 Do patients with cancer and clinicians see disease status the same way?
Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
🚨 NEW opportunity! 🚨
We’re recruiting a Translational Research Programme Manager to support delivery of the recently launched MRC-funded 𝗥𝗜𝗦𝗘 programme at @uom-dcs.bsky.social @manchester.ac.uk - based in the Withington campus.
🗓️ Deadline: 30th January 2026.
🔗 To find out more and to apply:
We’re recruiting a Translational Research Programme Manager to support delivery of the recently launched MRC-funded 𝗥𝗜𝗦𝗘 programme at @uom-dcs.bsky.social @manchester.ac.uk - based in the Withington campus.
🗓️ Deadline: 30th January 2026.
🔗 To find out more and to apply:
Translational Research Programme Manager :Paterson Building
As an equal opportunities employer we welcome applicants from all sections of the community regardless of age, sex, gender (or gender identity), ethnicity, disability, sexual orientation and transgender status. All appointments are made on merit.
www.jobs.manchester.ac.uk
January 12, 2026 at 5:49 PM
🚨 NEW opportunity! 🚨
We’re recruiting a Translational Research Programme Manager to support delivery of the recently launched MRC-funded 𝗥𝗜𝗦𝗘 programme at @uom-dcs.bsky.social @manchester.ac.uk - based in the Withington campus.
🗓️ Deadline: 30th January 2026.
🔗 To find out more and to apply:
We’re recruiting a Translational Research Programme Manager to support delivery of the recently launched MRC-funded 𝗥𝗜𝗦𝗘 programme at @uom-dcs.bsky.social @manchester.ac.uk - based in the Withington campus.
🗓️ Deadline: 30th January 2026.
🔗 To find out more and to apply:
🧬 Cell therapy in sarcoma: what do we know so far?
Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social
Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social
Cell therapy in sarcoma: current landscape and future directions
Sarcomas are rare malignancies of mesenchymal origin, characterized by significant biological and clinical heterogeneity. Many subtypes demonstrate limited sensitivity to standard systemic treatments,...
jitc.bmj.com
January 12, 2026 at 5:28 PM
🧬 Cell therapy in sarcoma: what do we know so far?
Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social
Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social
A big welcome to our #MedicalOncology colleagues from National Cancer Institute of Ukraine 🇺🇦. Looking forward to working with you all this week and beyond!
@mcrcnews.bsky.social
@christieinstitute.bsky.social
@mcrcnews.bsky.social
@christieinstitute.bsky.social
It's the final week of our SCALE project, in partnership with @NationalCancerInstitute Ukraine and we are delighted to welcome to The Christie today, cohort three of our Ukrainian Observers. Follow their journey.
#cancercare #cancereducation #internationaleducation #internationalobservers #ukraine
#cancercare #cancereducation #internationaleducation #internationalobservers #ukraine
January 12, 2026 at 9:11 AM
A big welcome to our #MedicalOncology colleagues from National Cancer Institute of Ukraine 🇺🇦. Looking forward to working with you all this week and beyond!
@mcrcnews.bsky.social
@christieinstitute.bsky.social
@mcrcnews.bsky.social
@christieinstitute.bsky.social
Reposted by Jon Lim, FRCP PhD
Congrats to the team of @reisesousalab.bsky.social for this beautiful work in @natimmunol.nature.com showing that "Neoantigen cross-presentation by cDC1 can determine the immune visibility of the tumor mutational landscape and sculpt cancer evolution by immunoediting"
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity - Nature Immunology
Here the authors show DNGR-1 expressed by cDC1s promotes CD8⁺ T cell priming to cytoskeletal neoantigens from dying tumor cells, thereby shaping cancer immune visibility and tumor evolution through im...
www.nature.com
January 6, 2026 at 12:51 PM
Congrats to the team of @reisesousalab.bsky.social for this beautiful work in @natimmunol.nature.com showing that "Neoantigen cross-presentation by cDC1 can determine the immune visibility of the tumor mutational landscape and sculpt cancer evolution by immunoediting"
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Jon Lim, FRCP PhD
Dendritic cells detect dead tumor cells using the DNGR-1 receptor, helping the immune system recognize and target cancer cells with specific mutations. This insight may inform future immunotherapies. doi.org/hbhtf6
Lifting cancer's invisibility cloak: Dying tumor cells alert the immune system
The immune system provides constant surveillance for the body, aiming to spot and eliminate disease-causing microbes or cancerous cells.
medicalxpress.com
January 5, 2026 at 3:18 PM
Dendritic cells detect dead tumor cells using the DNGR-1 receptor, helping the immune system recognize and target cancer cells with specific mutations. This insight may inform future immunotherapies. doi.org/hbhtf6
Reposted by Jon Lim, FRCP PhD
Thanks for highlighting our paper in your wonderful News & Views!
January 2, 2026 at 8:17 PM
Thanks for highlighting our paper in your wonderful News & Views!
The ‘Big Picture’: Immune Response produced by @wellcometrust.bsky.social.
🔗 www.stem.org.uk/resources/li...
🔗 www.stem.org.uk/resources/li...
January 4, 2026 at 10:25 PM
The ‘Big Picture’: Immune Response produced by @wellcometrust.bsky.social.
🔗 www.stem.org.uk/resources/li...
🔗 www.stem.org.uk/resources/li...
Reposted by Jon Lim, FRCP PhD
DNGR-1 enables cDC1 to sculpt cancer immunoediting through selective cross-presentation of F-actin-tethered neoantigens
@natimmunol.nature.com @reisesousalab.bsky.social
@crick.ac.uk
www.nature.com/articles/s41...
www.nature.com/articles/s41...
preview by @magarianblander.bsky.social
@natimmunol.nature.com @reisesousalab.bsky.social
@crick.ac.uk
www.nature.com/articles/s41...
www.nature.com/articles/s41...
preview by @magarianblander.bsky.social
January 2, 2026 at 8:52 PM
DNGR-1 enables cDC1 to sculpt cancer immunoediting through selective cross-presentation of F-actin-tethered neoantigens
@natimmunol.nature.com @reisesousalab.bsky.social
@crick.ac.uk
www.nature.com/articles/s41...
www.nature.com/articles/s41...
preview by @magarianblander.bsky.social
@natimmunol.nature.com @reisesousalab.bsky.social
@crick.ac.uk
www.nature.com/articles/s41...
www.nature.com/articles/s41...
preview by @magarianblander.bsky.social
Reposted by Jon Lim, FRCP PhD
Elegant proof that a DNGR-1–dependent mechanism isn’t just sensing tumors but editing them in carcinogenesis
A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure
Thanks for sharing @drjonlim.bsky.social & congrats 🥳
A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure
Thanks for sharing @drjonlim.bsky.social & congrats 🥳
January 4, 2026 at 1:12 PM
Elegant proof that a DNGR-1–dependent mechanism isn’t just sensing tumors but editing them in carcinogenesis
A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure
Thanks for sharing @drjonlim.bsky.social & congrats 🥳
A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure
Thanks for sharing @drjonlim.bsky.social & congrats 🥳
Reposted by Jon Lim, FRCP PhD
#WeekendRead! #DendriticCellPower! @reisesousalab.bsky.social @drjonlim.bsky.social &co show @natimmunol.nature.com that cDC1s exploit DNGR1 to crosspresent #tumor #neoantigens derived from F-actin binding proteins protecting against tumorigenesis but favoring cancer immunoediting!
Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity - Nature Immunology
Here the authors show DNGR-1 expressed by cDC1s promotes CD8⁺ T cell priming to cytoskeletal neoantigens from dying tumor cells, thereby shaping cancer immune visibility and tumor evolution through im...
doi.org
January 3, 2026 at 4:13 PM
#WeekendRead! #DendriticCellPower! @reisesousalab.bsky.social @drjonlim.bsky.social &co show @natimmunol.nature.com that cDC1s exploit DNGR1 to crosspresent #tumor #neoantigens derived from F-actin binding proteins protecting against tumorigenesis but favoring cancer immunoediting!
Reposted by Jon Lim, FRCP PhD
@drjonlim.bsky.social & @reisesousalab.bsky.social show cDC1s & DNGR1 favor "tethered" neoantigens from F-actin proteins, trapping them in necrotic debris for better cross-presentation! Calls for prioritizing these neoantigens for cancer vaccine design #Immunotherapy www.nature.com/articles/s41...
Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity - Nature Immunology
Here the authors show DNGR-1 expressed by cDC1s promotes CD8⁺ T cell priming to cytoskeletal neoantigens from dying tumor cells, thereby shaping cancer immune visibility and tumor evolution through im...
www.nature.com
January 2, 2026 at 7:19 PM
@drjonlim.bsky.social & @reisesousalab.bsky.social show cDC1s & DNGR1 favor "tethered" neoantigens from F-actin proteins, trapping them in necrotic debris for better cross-presentation! Calls for prioritizing these neoantigens for cancer vaccine design #Immunotherapy www.nature.com/articles/s41...